glp-1 receptor brain programs the neurovascular landscape: Cell Metabolism The evolving story of incretins
Description
HLA-B*5701 screening for hypersensitivity to abacavir
Newer glucose-lowering drugs and risk of gout: a network meta-analysis of randomized outcomes trials
In GK rats, E4 treatment significantly suppressed Evans blue leakage from retinal vessels
Significant weight reduction can lead to decreased skin elasticity, increased skin laxity, dryness, and subjective changes in skin texture
New York Medicaid (NYRx) excludes GLP-1 medications for weight loss under 18 NYCRR 505.3(g)(3)
Progression risk: NAFLD can progress to NASH (with inflammation), fibrosis, cirrhosis, and liver failure
